| 4601 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
58 |
| 4602 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
67 |
| 4603 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
47 |
| 4604 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
56 |
| 4605 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
55 |
| 4606 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
64 |
| 4607 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
66 |
| 4608 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
65 |
| 4609 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
63 |
| 4610 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
69 |
| 4611 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
63 |
| 4612 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2020 |
Standard Therapy |
Germany |
73 |
| 4613 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
63 |
| 4614 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2020 |
Standard Therapy |
Poland |
69 |
| 4615 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2020 |
Standard Therapy |
Poland |
70 |
| 4616 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2020 |
Standard Therapy |
Poland |
63 |
| 4617 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2020 |
Standard Therapy |
Poland |
62 |
| 4618 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2020 |
Standard Therapy |
Poland |
43 |
| 4619 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2020 |
Standard Therapy |
Poland |
63 |
| 4620 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2020 |
Standard Therapy |
Poland |
52 |
| 4621 |
Apheresis |
Allogeneic |
Myeloproliferative Neoplasms |
Hematology |
2020 |
Standard Therapy |
Poland |
68 |
| 4622 |
Apheresis |
Allogeneic |
Myeloproliferative Neoplasms |
Hematology |
2020 |
Standard Therapy |
Poland |
40 |
| 4623 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2020 |
Standard Therapy |
Poland |
71 |
| 4624 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2020 |
Standard Therapy |
Poland |
64 |
| 4625 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
65 |
| 4626 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
58 |
| 4627 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
63 |
| 4628 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
58 |
| 4629 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
62 |
| 4630 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
53 |
| 4631 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
57 |
| 4632 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
69 |
| 4633 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
62 |
| 4634 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
34 |
| 4635 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
42 |
| 4636 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
62 |
| 4637 |
Apheresis |
Autologous |
Non-Hodgkin-Lymphoma-Relapse |
Hematology |
2020 |
Standard Therapy |
Germany |
56 |
| 4638 |
Apheresis |
Autologous |
Non-Hodgkin-Lymphoma-Relapse |
Hematology |
2020 |
Standard Therapy |
Germany |
67 |
| 4639 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
68 |
| 4640 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
52 |
| 4641 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
64 |
| 4642 |
Apheresis |
Allogeneic |
Paroxysmal Nocturnal Hemoglobinuria (Pnh) |
Hematology |
2020 |
Standard Therapy |
Poland |
57 |
| 4643 |
Apheresis |
Allogeneic |
Perforin Deficiency |
Hematology |
2020 |
Standard Therapy |
Poland |
2 |
| 4644 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
59 |
| 4645 |
Apheresis |
Autologous |
Primary Cerebral Diffuse Large B-Cell Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
66 |
| 4646 |
Apheresis |
Autologous |
Primary Cerebral Diffuse Large B-Cell Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
59 |
| 4647 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
63 |
| 4648 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
61 |
| 4649 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
51 |
| 4650 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
66 |
| 4651 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Poland |
61 |
| 4652 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Germany |
54 |
| 4653 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2020 |
Standard Therapy |
Germany |
58 |
| 4654 |
Apheresis |
Allogeneic |
Purine Nucleoside Phosphorylase Deficiency |
Hematology |
2020 |
Standard Therapy |
Poland |
1 |
| 4655 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2020 |
Standard Therapy |
Poland |
43 |
| 4656 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2020 |
Standard Therapy |
Poland |
76 |
| 4657 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2020 |
Standard Therapy |
Poland |
57 |
| 4658 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2020 |
Standard Therapy |
Germany |
66 |
| 4659 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2020 |
Standard Therapy |
Germany |
56 |
| 4660 |
Apheresis |
Autologous |
Secondary B-Cell Non-Hodgkin-Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
73 |
| 4661 |
Apheresis |
Autologous |
Secondary Diffuse Large B-Cell Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
54 |
| 4662 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2020 |
Standard Therapy |
Poland |
9 |
| 4663 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2020 |
Standard Therapy |
Poland |
53 |
| 4664 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2020 |
Standard Therapy |
Poland |
52 |
| 4665 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2020 |
Standard Therapy |
Poland |
2 |
| 4666 |
Apheresis |
Allogeneic |
Sezary Syndrome |
Hematology |
2020 |
Standard Therapy |
Poland |
44 |
| 4667 |
Apheresis |
Allogeneic |
T-Cell Acute Lymphoblastic Leukemia |
Hematology |
2020 |
Standard Therapy |
Poland |
14 |
| 4668 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
57 |
| 4669 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
29 |
| 4670 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
64 |
| 4671 |
Apheresis |
Allogeneic |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
63 |
| 4672 |
Apheresis |
Allogeneic |
T-Cell-Lymphoma |
Hematology |
2020 |
Standard Therapy |
Poland |
29 |
| 4673 |
Apheresis |
Autologous |
T-Cell-Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
51 |
| 4674 |
Apheresis |
Autologous |
T-Cell-Lymphoma |
Hematology |
2020 |
Standard Therapy |
Germany |
60 |
| 4675 |
Apheresis |
Allogeneic |
T-Cell-Prolymphocytic Leukemia |
Hematology |
2020 |
Standard Therapy |
Poland |
55 |
| 4676 |
Apheresis |
Allogeneic |
T-Cell-Prolymphocytic Leukemia |
Hematology |
2020 |
Standard Therapy |
Poland |
74 |
| 4677 |
Apheresis |
Allogeneic |
Β – Thalassemia |
Hematology |
2020 |
Standard Therapy |
Poland |
6 |
| 4678 |
Apheresis |
Allogeneic |
Β – Thalassemia Major |
Hematology |
2020 |
Standard Therapy |
Poland |
17 |
| 4679 |
Adipose Tissue |
Autologous |
Alopecia |
Dermatology |
2020 |
Experimental Therapy |
Poland |
68,5 |
| 4680 |
Adipose Tissue |
Autologous |
Chondromalacia |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
45,9 |
| 4681 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
52,8 |
| 4682 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
63,4 |
| 4683 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
41,1 |
| 4684 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
34,8 |
| 4685 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
48,1 |
| 4686 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
57,11 |
| 4687 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
59,8 |
| 4688 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
35,1 |
| 4689 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
61,8 |
| 4690 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
56,5 |
| 4691 |
Adipose Tissue |
Autologous |
Gonarthrosis; Shoulder Osteoarthritis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
42,5 |
| 4692 |
Adipose Tissue |
Autologous |
Internal Damage To The Knee Joint |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
53,6 |
| 4693 |
Adipose Tissue |
Autologous |
Internal Damage To The Knee Joint |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
49,2 |
| 4694 |
Adipose Tissue |
Autologous |
Omarthrosis |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
70,1 |
| 4695 |
Adipose Tissue |
Autologous |
Other Acquired Deformities Of The Ankle And Foot |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
41,6 |
| 4696 |
Adipose Tissue |
Autologous |
Scar |
Dermatology |
2020 |
Clinical Trial |
Poland |
no data |
| 4697 |
Adipose Tissue |
Autologous |
Soft Tissue Diseases Related To Use, Overload And Pressure |
Orthopedy |
2020 |
Experimental Therapy |
Poland |
61,1 |
| 4698 |
Cord Tissue |
Allogeneic – Unrelated |
Limb-Girdle Muscular Dystrophy |
Neurology |
2019 |
Experimental Therapy |
Poland |
5,3 |
| 4699 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2019 |
Experimental Therapy |
Poland |
1,9 |
| 4700 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2019 |
Experimental Therapy |
Poland |
6,1 |